Assessing Non-adjunctive CGM Safety at Home and in New Markets

Diabetes Mellitus Clinical Trial

— ANSHIN  

Official title:

Assessing Non-adjunctive CGM Safety at Home and in New Markets

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04585139
• Other study ID #: PTL-903833
• Status: Completed
• Phase: N/A
• Start date: October 6, 2020
• Est. completion date: February 7, 2022

Study information

• Verified date: July 2022
• Source: DexCom, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to examine whether non-adjunctive (without having to double check using another method) use of Continuous Glucose Monitoring improves A1c in adults or children with diabetes managed by intensive insulin therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: February 7, 2022
• Est. primary completion date: February 7, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria

• Age 2 years or older

• A diagnosis of T1D or T2D made at least 6 months prior to enrollment. At least 20 adult participants will have T1D; and 10 will have T2D; 10 participants will be over age 65 years.

• Using IIT (either an insulin pump or MDI)

• HbA1c value = 7.5% (= 58 mmol/mol) measured by local lab within prior 30-days before enrollment or by point of care at time of screening.

• eGFR = 30 within the last 90-days prior to enrollment (adult participants only)

• Currently performing 2 or more SMBG fingersticks a day by historical average and willing to continue this during the blinded CGM wear.

Exclusion Criteria

• Use of real-time or intermittently scanned CGM in the 6 months prior to enrollment.

• BMI > 45.

• Anticipated changes to insulin delivery method or insulin formulation(s).

• Insulin formulation changes within class will be permitted if required per formulary change and represent equivalent therapy (eg: insulin lispro change to insulin aspart).

• Pregnancy (as demonstrated by a positive test at study entry) at time of screening or are planning to become pregnant during the study.

• Applicable only to women of reproductive potential.

• Planned or currently using weight reduction medications, programs or surgery. Defined as 1) using weight loss medications and losing weight (e.g. chronic use of weight loss medications with stable weight is not exclusionary) or planning on using weight loss prescription medication during the study; 2) currently using or planning on initiating a modified fasting program (e.g. protein-sparing diet plans) during the study; or 3) bariatric surgical procedure within the past year or plans for undergoing bariatric surgery during the study.

• Concomitant disease or condition that may compromise patient safety including, but not limited to; severe mental illness, a diagnosed or suspected eating disorder or any uncontrolled long-term medical/psychiatric condition that would interfere with study- related tasks or visits, including ongoing treatment for a significant malignancy. These assessments/conditions are made at investigator's discretion.

• Known (or suspected) significant allergy to medical-grade adhesives.

• Any condition, per investigator assessment, that could impact the stability of the HbA1c measurement, for example,

• Acute or chronic blood loss or bleeding disorder,

• Red blood cell transfusion or erythropoietin, administration in the 3 months prior to enrollment,

• Or red blood cell transfusion or erythropoietin administration anticipated during the course of the study.

• Anticipated acute use of oral or injectable glucocorticoids that could affect glycemic control and impact HbA1c, for example,

• Frequent steroid bursts used for inflammatory arthritis or inflammatory bowel disease,

• Or recurrent lumbar epidural steroid injections,

• Current treatment with hydroxyurea

• Participation in another pharmaceutical or device trial at the time of enrollment or during the study.

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Device:
• Phase 1- Introduction to Dexcom G6 CGM
Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy

Locations

Country	Name	City	State
United States	Las Vegas Endocrinology	Henderson	Nevada

Sponsors (2)

Lead Sponsor	Collaborator
DexCom, Inc.	Jaeb Center for Health Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HbA1c	Phase 1 change in HbA1c for the adult cohort only.	16 weeks